project id: TCGA-BLCA; case submitter id: TCGA-KQ-A41N; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.39; rna integrity number: 7.5; age at index: 73; days to birth: -26837; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Alive; year of birth: 1938; age at diagnosis: 26837; ajcc clinical t: T2b; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1604.0; icd 10 code: C67.6; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Ureteric orifice; synchronous malignancy: No; tissue or organ of origin: Ureteric orifice; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 2.73972602739726; pack years smoked: 50.0; is ffpe: false; composition: Not Reported; initial weight: 760.0; sample id: 85d9b3ae-d14a-445f-83bf-e4a9f9b076b8; sample submitter id: TCGA-KQ-A41N-01A; portion id: 8f18f29a-2349-4e47-b7a9-396f16dd1706; portion submitter id: TCGA-KQ-A41N-01A-11; slide id: 0325399a-0ac8-4fe3-b09f-3352a8b0fb0e; slide submitter id: TCGA-KQ-A41N-01A-01-TSA; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 15.0; percent tumor cells: 85.0; percent tumor nuclei: 85.0; section location: TOP;